Could a person with facial, lip, and nasal telangiectasias that bleed rarely and a 2.9 cm inferior mesenteric venous varix (not an arteriovenous malformation) have hereditary hemorrhagic telangiectasia?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

HHT Diagnosis: Possible/Suspected Based on Curaçao Criteria

This person meets criteria for "possible" or "suspected" HHT with two of the four Curaçao criteria present, warranting further evaluation including family history assessment, screening for additional visceral lesions, and consideration of genetic testing. 1, 2

Applying the Curaçao Diagnostic Criteria

The standardized Curaçao criteria require assessment of four specific features 1, 3:

Criteria Present in This Case (2/4):

  1. Telangiectases: Multiple telangiectases at characteristic sites (facial, lip, and nasal) - PRESENT
  2. Visceral lesions: The 2.9 cm inferior mesenteric venous varix requires careful interpretation - POSSIBLY PRESENT

Criteria Not Yet Assessed (2/4):

  1. Epistaxis: Spontaneous, recurrent nosebleeds - NOT MENTIONED (the telangiectasias "bleed rarely" but unclear if this refers to epistaxis specifically)
  2. Family history: First-degree relative with HHT - NOT PROVIDED

Critical Diagnostic Interpretation

The venous varix presents a diagnostic challenge. While you specify it is "not an AVM," the Curaçao criteria list "gastrointestinal telangiectases (with or without bleeding)" as qualifying visceral lesions 1. A mesenteric venous varix could represent:

  • An atypical vascular malformation consistent with HHT's spectrum
  • A manifestation of the same underlying vascular dysregulation
  • An incidental finding unrelated to HHT

HHT diagnosis classification 1, 3:

  • Definite: 3 or more criteria = NOT MET
  • Possible/Suspected: 2 criteria = CURRENT STATUS
  • Unlikely: Fewer than 2 criteria = NOT APPLICABLE

Essential Next Steps for Diagnosis

1. Complete Clinical Assessment

  • Detailed epistaxis history: Frequency, severity, age of onset, need for medical intervention 4
  • Family history: Screen for HHT in first-degree relatives, recurrent nosebleeds, or known vascular malformations 1, 2
  • Additional mucocutaneous examination: Oral cavity (tongue, hard palate), fingers for additional telangiectases 4

2. Screen for Additional Visceral Involvement

Given the potential diagnosis, screening is critical to prevent life-threatening complications 2, 5:

  • Pulmonary AVMs: Contrast echocardiography or chest CT (70-90% of HHT patients have pulmonary AVMs) 6, 5
  • Cerebral AVMs: Brain MRI with and without contrast 2, 5
  • Hepatic vascular malformations: Doppler ultrasound as first-line imaging 1
  • Complete GI evaluation: Given the mesenteric varix, assess for GI telangiectases via endoscopy 2, 7

3. Genetic Testing Consideration

If clinical suspicion remains high, molecular testing for ENG (endoglin) and ACVRL1/ALK1 genes can confirm diagnosis, though sensitivity is not 100% 1, 2, 5. Approximately 85% of HHT cases have identifiable mutations in these genes 5.

Clinical Significance and Pitfalls

Common diagnostic pitfall: HHT is frequently underdiagnosed or diagnosed with significant delay 4, 8. The absence of recurrent epistaxis does not exclude HHT, though it occurs in >90% of affected adults 7, 9. Some patients remain asymptomatic until later in life 8.

Morbidity and mortality concerns 1, 10:

  • Untreated pulmonary AVMs can cause paradoxical emboli leading to stroke or brain abscess
  • Cerebral AVMs risk hemorrhage
  • Chronic bleeding leads to severe iron-deficiency anemia requiring transfusions
  • High-output heart failure from hepatic shunting

Quality of life impact: Recurrent bleeding causes significant psychosocial morbidity, social isolation, and employment difficulties 7, 9.

Management Implications

If HHT is confirmed or remains suspected:

  • Avoid liver biopsy in proven or suspected HHT patients 1
  • Implement screening protocols for asymptomatic visceral AVMs 2
  • Consider iron supplementation and monitor for anemia 2, 7
  • Be aware of increased venous thromboembolism risk in HHT patients, particularly those >65 years (incidence 45.1/1,000 patient-years) 11
  • Refer to HHT specialty center for comprehensive management 2

The presence of characteristic telangiectases plus a visceral vascular abnormality warrants aggressive pursuit of the diagnosis, as early identification enables preventive screening and treatment that can prevent catastrophic complications like stroke, brain abscess, or massive hemorrhage 2, 5.

References

Guideline

clinical practice guideline: nosebleed (epistaxis).

Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2020

Research

Hereditary hemorrhagic telangiectasia: an overview of diagnosis, management, and pathogenesis.

Genetics in medicine : official journal of the American College of Medical Genetics, 2011

Research

What's new in hereditary hemorrhagic telangiectasia?

Hematology. American Society of Hematology. Education Program, 2025

Guideline

vascular disorders of the liver.

Hepatology, 2009

Related Questions

What causes epistaxis in hereditary hemorrhagic telangiectasia?
Can hereditary hemorrhagic telangiectasia cause a 2.9‑cm inferior mesenteric venous varix?
What is the typical presentation of hereditary hemorrhagic telangiectasia (HHT)?
Is a 2.9 cm inferior mesenteric venous varix considered an arteriovenous malformation for purposes of hereditary hemorrhagic telangiectasia classification under the Curaçao criteria?
In a patient with suspected hereditary hemorrhagic telangiectasia (HHT) in primary care, what are the next steps and appropriate referrals?
Is it permissible under Medicare regulations to use EzPAP (positive expiratory pressure device), Acapella (oscillating positive expiratory pressure device), Cough Assist (mechanical insufflator‑exsufflator), and Therapy Vest (high‑frequency chest wall oscillation) as a blanket wellness program for skilled nursing facility and long‑term care patients without documented respiratory indications, or does this constitute fraudulent billing?
In a patient with suspected type 1 diabetes, especially with atypical features, which autoimmune antibody tests (glutamic acid decarboxylase 65 kDa antibodies [GAD65], insulinoma‑associated antigen‑2 antibodies [IA‑2], zinc transporter‑8 antibodies [ZnT8], and insulin autoantibodies [IAA] if on insulin) should be ordered at diagnosis and how should the results be interpreted?
What is the recommended prednisone taper dosing for pyoderma?
In a 69-year-old patient on paliperidone (Invega), escitalopram (Lexapro), trazodone, valproic acid (Depakote), and carbidopa/levodopa (Sinemet) with worsening tremors, should I taper the paliperidone and restart a benzodiazepine or switch to quetiapine (Seroquel)?
Is it safe to use topical lidocaine as needed for pain during vaginal intercourse?
In a patient with NSTEMI whose family declines invasive intervention, currently taking clopidogrel (Plavix) 75 mg daily and allergic to aspirin, should I give a ticagrelor (Brilinta) loading dose before starting the maintenance dose of 90 mg twice daily, or can I start ticagrelor without a loading dose after stopping clopidogrel?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.